Please assess the completion status of the following clinical trial:

Trial Title: Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subjects with 5 to 20 clinically typical, visible and, discrete, nonhyperkeratotic and non-hypertrophic AKs within a selected treatment area of sun-damaged skin on either:~* The full face~* The full balding scalp~* A contiguous area of approximately 250 cm2 on trunk or extremities~Exclusion Criteria:~Location of the treatment area (full face, full balding scalp or chest) within 5 cm of an incompletely healed wound or within 5 cm of a suspected basal cell carcinoma (BCC) or SCC.~Previously assigned treatment in this clinical trial or previously participated in a clinical trial in the LEO 43204 programme.~Treatment with ingenol mebutate gel in the selected treatment area within the last 12 months~Lesions in the treatment area that have: atypical clinical appearance (e.g. cutaneous horns) and/or, recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 43204, 0.018% once daily for 3 days (Type: EXPERIMENTAL): None
- LEO 43204, 0.037% once daily for 3 days (Type: EXPERIMENTAL): None
- LEO 43204, 0.1% once daily for 3 days (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).